[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-cancer":32},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,141,0,25,[9,59,91,161,183,212,233,268,298,327,355,377,410,459,487,521,559,582,603,624,650,670,691,717,742],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100597545","distance-based-exercise-to-preserve-function-and-prevent-disability-100597545",false,"NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":20,"type":21},104,"ESTIMATED","INTERVENTIONAL",[24],"NA","This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","Sarcoma","RECRUITING","2026-07-01",{"date":49,"type":50},"2026-07-02","ACTUAL",{"date":52,"type":50},"2026-02-11",{"date":54,"type":21},"2027-08-31",{"name":56,"class":57},"Alliance for Clinical Trials in Oncology","OTHER",18,{"id":60,"slug":61,"hasResults":12,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":17,"minAge":67,"maxAge":4,"enrollmentInfo":68,"targetDuration":70,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":74,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100607264","exopert-emerald-clinical-study-100607264","NCT07186296","EXoPERT EMERALD Clinical Study","EXoPERT EMERALD: Early Multi-cancer Study of EV's Ramen-AL Linked Diagnosis Clinical Study Protocol","Inclusion Criteria:\n\n* Subject aged 45 years or older with a biopsy-proven or clinically suspected primary lung, breast, colorectal, pancreatic, or ovarian cancer, based on objective findings such as radiological, serological, endoscopic, or cytological findings, whose blood was collected prior to any systemic or definitive therapy for the cancer.\n* Subjects who are willing and able to provide written informed consent.\n* Subjects who are willing and able to comply with the study requirements.\n\nExclusion Criteria:\n\n* Any history of cancer diagnosed and treated within 5 years prior to the date of consent.\n* Subjects with a history of previous cancer treatment via surgical resection, hormonal cancer treatment, chemotherapy, radiotherapy within the past 6 months for recent cancer diagnosis.\n* Subjects who have any history of an allogeneic bone marrow, stem cell transplant, or solid organ transplant.\n* Subjects who are pregnant or breastfeeding women.\n* Subjects who have consented and have undergone treatment in any other cancer related clinical trials withinthe past 6 months.\n* Subjects who are currently in active treatment for drug abuse.\n* Subjects who have received any treatment related to lung, breast, colorectal, pancreatic, or ovarian nodules, such as hormones prior to entering the study.\n* Unsuitable sample for testing due to contamination, hemolysis, etc.",true,"45 Years",{"count":69,"type":21},1400,"1 Day","OBSERVATIONAL","The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software. The software analyzes surface-enhanced Raman spectroscopy (SERS) profiles of extracellular vesicles (EVs) extracted from human plasma for the early detection of multiple cancers, including lung, ovarian, breast, pancreatic, and colorectal cancers.",[30,32,42,41,39],[75,76,77,78,79,80],"Early-stage","In vitro Diagnostic Test","Artificial intelligence","extracellular vesicles","multi cancer diagnosis","cancer","2026-06-28",{"date":47,"type":50},{"date":84,"type":50},"2025-05-09",{"date":86,"type":21},"2026-08-31",{"name":88,"class":89},"EXoPERT","INDUSTRY",9,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":66,"sex":17,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":102,"studyType":71,"phases":4,"briefSummary":103,"conditions":104,"keywords":141,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":160},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals","19 Years","110 Years",{"count":101,"type":21},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[42,105,39,34,106,32,44,107,28,108,109,110,36,38,111,112,113,114,115,37,116,43,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,30,133,134,45,135,136,41,33,137,138,139,140],"Thyroid Cancer","Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Penile Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Melanoma","Unknown Primary Tumor","Multiple Myeloma","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[42,105,142,143,144,145,146,147,148,149,30,150,139,140],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":153,"type":50},"2026-06-29",{"date":155,"type":50},"2013-11-01",{"date":157,"type":21},"2099-12",{"name":159,"class":57},"University of Nebraska",42,{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":4},"100644786","improving-prognostication-in-colon-cancer-100644786","NCT07673393","Improving Prognostication in Colon Cancer","Improving Prognostication of Localised Colon Cancer by Combining Liquid Biopsy and Histology: a Multicentric, Prospective Study","MARBLE","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Male and female participants, at least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Newly diagnosed primary colon tumor clinically and\u002For histologically consistent with localized colon adenocarcinoma and planned for curative-intent surgical resection.\n4. Clinical stage compatible with non-metastatic disease at time of screening and considered eligible for standard curative-intent management according to investigator assessment.\n5. WHO (ECOG) performance status ≤ 3 at baseline.\n\nExclusion Criteria:\n\n1. Participant has been diagnosed with metastatic disease (Stage IV)\n2. Participant has been diagnosed with rectal cancer\n3. Participant has been diagnosed with synchronous primary colon tumors (i.e., presence of two or more primary colon tumors detected simultaneously at diagnosis)\n4. Participant has received prior systemic therapy (chemotherapy, targeted therapy, immunotherapy, or radiotherapy) for colon cancer\n5. Participation in an interventional Study with an investigational medicinal product (IMP) or device within 30 days prior to inclusion.\n6. Participant had prior history of colon cancer requiring systemic treatment or major colorectal oncologic surgery.\n7. Any severe, uncontrolled, or life-threatening medical condition that, in the opinion of the investigator, could interfere with study participation, interpretation of study assessments, or pose excessive risk to the participant (e.g. severe cardiac, hepatic, renal, or uncontrolled infectious disease).",{"count":170,"type":21},400,"The goal of this study is to test better ways to predict if cancer will return after surgery in adults (18+) who have been diagnosed with stage II or III colon cancer.\n\nThe main questions it aims to answer are:\n\n* Can computer programs (Artificial Intelligence) and special blood tests give more accurate information about the risk of cancer returning than the methods doctors use today?\n* Does combining these new tests help doctors better understand which patients really need chemotherapy and which do not?\n\nResearchers will compare the new computer and blood tests to the standard hospital methods used now to see if the new way is more accurate in predicting the cancer's behavior\n\nParticipants will:\n\n* Sign a form saying they agree to take part in the study\n* Have their standard surgery to remove the tumor\n* Give a few extra teaspoons of blood during their regular, scheduled hospital visits\n* Allow researchers to scan and study a small piece of the tumor that was already removed during surgery\n* Continue with their normal hospital check-ups for up to five years so researchers can track their health",[32,173],"Colon Adenocarcinoma","NOT_YET_RECRUITING","2026-06-22",{"date":153,"type":50},{"date":178,"type":21},"2026-09",{"date":180,"type":21},"2033-09",{"name":182,"class":57},"Universitaire Ziekenhuizen KU Leuven",{"id":184,"slug":185,"hasResults":12,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":196,"conditions":197,"keywords":199,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100643932","phase-3-evaluation-of-nuvastatictm-in-reducing-cancer-related-fatigue-in-stage-iv-colon-cancer-patients-undergoing-first-line-chemotherapy-100643932","NCT07669519","Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","NuvastaticTM","Inclusion Criteria:\n\n1. Male and female Patients who are ≥18 and ≤65 years of age, who are willing to voluntarily provide consent for participation in the study.\n2. Patients with colon cancer planned or scheduled to receive standard chemotherapy treatment for at least 3 cycles respectively.\n3. Patients must have a confirmed diagnosis of colon cancer as per standard guideline.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.\n5. The patient has stable haemoglobin (≥ 9 g\u002FdL) throughout the screening.\n6. Life expectancy ≥ 6 months, as per Investigator's judgment\n7. Patients with co-morbidities or medical conditions including Type 2 DM, hypertension and are deemed stable by the investigator can be included in the study\n8. At screening patients with stable fatigue, has a newly developed fatigue OR worsening of fatigue scoring as assessed by BFI should be included.\n9. Starting first-line chemo\n\nExclusion Criteria:\n\n1. Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the Investigator's clinical judgment.\n2. Patients who have stage IV Disease\n3. Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with study drug.\n4. Prior metastatic chemo, targeted\u002Fimmunotherapy, severe comorbidities\n5. Female patients who are pregnant or breast-feeding.\n6. Patients with known hepatitis C virus, hepatitis B virus, HIV infection.\n7. Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.\n8. Patients with uncontrolled pain, who in the opinion of the Investigator are not eligible for the study. '\n9. Patients with planned therapy or treatment with another investigational agent.\n10. Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.","65 Years",{"count":193,"type":21},180,[195],"PHASE3","The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.\n\nThe main questions it aims to answer are:\n\nDoes Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population?\n\nResearchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile.\n\nParticipants will:\n\nReceive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \\~60 treatment days).\n\nContinue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment.\n\nComplete patient diaries and fatigue assessments as per protocol.",[198,32],"Fatigue",[32,200,201,202,203],"Cancer-Related Fatigue","Nuvastatic","Randomized Double-Blind Placebo-Controlled Trial","First-Line Chemotherapy",{"date":151,"type":50},{"date":206,"type":50},"2025-08-18",{"date":208,"type":21},"2027-03-31",{"name":210,"class":89},"Natureceuticals Sdn Bhd",6,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":189,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":220,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":227,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":211},"100643923","phase-3-a-randomized-double-blind-placebo-controlled-parallel-group-comparative-phase-iii-study-to-evaluate-the-efficacy-and-safety-of-nuvastatic-300mg-capsule-in-reducing-cancer-tumor-in-patients-with-metastatic-colorectal-cancer-receiving-standard-chemotherapy-100643923","NCT07669454","A Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative, Phase III Study to Evaluate the Efficacy and Safety of Nuvastatic® 300mg Capsule in Reducing Cancer-Tumor in Patients With Metastatic Colorectal Cancer Receiving Standard Chemotherapy.","Inclusion Criteria:\n\n* Male and female patients who are ≥18 and ≤65 years of age, who are willing to voluntarily provide consent for participation in the study.\n* Patients with metastatic colorectal cancer planned or scheduled to receive standard chemotherapy treatment for at least 6 cycles respectively.\n* Patients must have a confirmed diagnosis of metastatic colorectal cancer as per standard guidelines.\n* Patients must have at least one tumor lesion with ≥ 1cm in one dimension that is radiographically apparent on computed tomography (CT) or magnetic resonance imaging (MRI).\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.\n* Life expectancy ≥ 6 months, as per investigator's judgment.\n* The patient has stable hemoglobin (≥ 9 g\u002FdL)throughout the screening.\n* Patients with co-morbidities or medical conditions including Type 2 diabetes mellitus (DM), hypertension who are deemed stable by the investigator can be included in the study.\n\nExclusion Criteria:\n\n* Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the investigator's clinical judgment.\n* Patients with an inability to understand local language(s) for scales used for evaluations, i.e., EORTC QLQ-C30, BFI, SF-36 and VAS-F.\n* Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with the study drug.\n* Patients with any delay in chemotherapy treatment such that the screening period extends beyond 21 days.\n* Patients with known central nervous system (CNS) are involved by metastatic cancer.\n* Patients with any serious, uncontrolled, non-malignant medical or psychiatric disorder, or any other medical condition which in the opinion of the investigator may affect the patient's safety or study participation and conduct.\n* Female patients who are pregnant or breastfeeding.\n* Patients with known hepatitis C virus, hepatitis B virus, HIV infection.\n* Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the investigator.\n* Patients with uncontrolled pain who, in the opinion of the investigator, are not eligible for the study.\n* Patients with known hypersensitivity or intolerance of rosmarinic acid, caffeic acid, and other related phenolic compounds as well as excipients in the Nuvastatic® 300 mg or placebo treatment.\n* Patients with planned therapy or treatment with another investigational agent.\n* Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.",{"count":219,"type":21},250,[195],"The goal of this clinical trial is to evaluate whether Nuvastatic 300 capsule can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.\n\nThe main questions it aims to answer are:\n\nDoes Nuvastatic 300 capsule significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic 300 capsule safe and well tolerated in this patient population?\n\nResearchers will compare Nuvastatic 300 capsule vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile.\n\nParticipants will:\n\nReceive Nuvastatic 300 capsule or placebo capsules (3 times per day) for 6 cycles of 20 days each (total \\~120 treatment days).\n\nContinue their standard first-line chemotherapy regimen. Provide blood samples assessment at Screening and End of Treatment. Complete patient diaries and fatigue assessments as per protocol.",[223,32],"Fatigue Related to Cancer Treatment",[201,32,225,226,203],"Cancer related fatigue","Randomized double blind placebo controlled trial",{"date":151,"type":50},{"date":229,"type":50},"2025-10-01",{"date":231,"type":21},"2026-11-30",{"name":210,"class":89},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":22,"phases":242,"briefSummary":244,"conditions":245,"keywords":249,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":267},"100414594","phase-1-a-trial-of-rsc-1255-for-treatment-of-patients-with-advanced-malignancies-100414594","NCT04678648","A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies","A Phase Ia\u002FIb, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of RSC-1255 Alone or in Combination With Hydroxychloroquine in Patients With Advanced Solid Tumor Malignancies","Inclusion Criteria (Key Factors):\n\n1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following:\n\n   * Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition\n   * Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit\n   * Malignancy has progressed on standard therapy\n2. Has evaluable or measurable tumor(s) in dose-escalation by standard radiological and\u002For laboratory assessments as applicable to their malignancy.\n3. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG).\n4. Is age ≥ 18 years.\n5. Has either tissue agnostic tumors and documented RAS mutations or with glioblastoma with or without mutation in RAS\n\nExclusion Criteria (Key Factors):\n\n1. Participants receiving cancer therapy at the time of enrollment.\n2. Any clinically significant disease or condition affecting a major organ system.\n3. Significant cardiovascular disease or electrocardiogram (ECG) abnormalities.\n4. Known Gilbert's disease.\n5. Has had a previous (within 2 years) or has a current malignancy other than the target cancer.\n6. Intermittent hypokalemia\n7. Grade 1 or higher nausea, vomiting, diarrhea at baseline due to underlying disease",{"count":241,"type":21},134,[243],"PHASE1","RSC-101 is a Phase 1a\u002F1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.",[246,247,39,32,248,42],"Advanced Malignant Solid Neoplasm","RAS Mutation","Glioblastoma",[250,251,252,253,254,255,248,256,257,258],"Malignancy","Cancer","Refractory","RAS mutation","Lung","Colon","RSC-1255","Progression","Pancreatic",{"date":260,"type":50},"2026-06-23",{"date":262,"type":50},"2021-03-03",{"date":264,"type":21},"2027-01-30",{"name":266,"class":89},"RasCal Therapeutics, Inc.",3,{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100622718","mainstreaming-genetics-evaluation-of-a-digital-application-to-scale-and-spread-oncologist-initiated-genetic-testing-100622718","NCT07387263","Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing","Inclusion Criteria:\n\n* Receiving germline testing related to primary cancer condition initiated by oncologist\n* 18 years old or older.\n* Speak and read English\n\nExclusion Criteria:\n\n* Receiving cancer genetic testing via a referral to a genetics clinic\n* Do not speak or read English\n* Under 18 years of age\n* Determined to have diminished, marginal and or fluctuating decisional capacity\n* Lack access to internet or an electronic device",{"count":193,"type":21},[24],"Genetic testing can alter therapy and surgical management for cancer patients and is therefore indicated as a first-line test for many newly diagnosed patients, including breast, ovarian, pancreatic, prostate and colon\u002FGI patients. To reduce pressure on already constrained genetics clinics across Canada, some cancer centres are 'mainstreaming' genetic testing - whereby genetic testing is initiated and mediated by oncologists without traditional pre-test genetic counseling (GC) often using some form of paper-based patient pamphlets or videos. There is no standard, evidence-based approach to mainstreaming, leading to significant practice variation, a lack of coordinated care and ultimately, negative psychological impacts on patients. Digital solutions can address these gaps by providing a standardized, coordinated and patient-centered approach to deliver cancer genetic education. However, digital solutions for providing cancer genetics services are uncommon and clinical-effectiveness and service delivery outcomes have not been well-assessed. This study will test a digital mainstreaming platform called the Genetics Adviser for Mainstream care to assess its effectiveness in improving psychological outcomes and patient-centred care for mainstream cancer patients compared to standard of care.",[251,30,43,32,278,41,42],"GI Cancers",[280,281,282,283,284,251,285,286,287],"Cancer Genetic Testing","Randomized Controlled Trial","Digital Tool","Mainstreaming","Genetic counseling","Genetic testing","Service Delivery","Alternative service delivery model","2026-06-19",{"date":290,"type":50},"2026-06-24",{"date":292,"type":50},"2026-04-30",{"date":294,"type":21},"2027-03",{"name":296,"class":57},"Unity Health Toronto",2,{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":17,"minAge":304,"maxAge":305,"enrollmentInfo":306,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":308,"conditions":309,"keywords":310,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":326},"100254821","genomic-services-research-program-100254821","NCT02595957","Genomic Services Research Program","* ELIGIBILITY CRITERIA:\n\nWe employ a referral form through SurveyMonkey to receive referrals from recruitment partners or self-referrals. This serves as an intake form and self-reported eligibility review. This form asks for contact information, key information about the prospective participant s SF,\n\nand subjective understanding of their result.\n\nIf we conclude, based on a review of the SF and available personal and\u002For family history, that the pathogenicity of the SF is not at least likely pathogenic, that participant may be eligible for the survey, interview, and\u002For re-contact for future follow-up, but will not complete any other protocol procedures (such as cascade testing). If a participant is consented and information arises during the social and behavioral study procedures that lead study staff to believe the genetic result does not qualify as an SF, the participant will be\n\nconsidered a screen failure and will not continue with study procedures.\n\nWe plan to offer enrollment in this protocol to English- or Spanish-speaking recipients of SF. We do not have trained staff who can conduct the interviews in languages other than English and Spanish.\n\nIf a caregiver of a minor or adult who is unable to consent is enrolled as an index participant to complete the survey and interview on behalf of the SF recipient, they may also be eligible for cascade testing to relate presence of an SF-related phenotype in a family member with presence or absence of SF genotype.\n\n-We may enroll a child in this protocol if he\u002Fshe is the only person in his\u002Fher family who has the SF, is symptomatic of the disease, or is in the age range to receive screening for the disease (e.g., Wilson disease and familial hypercholesterolemia have childhood onset).\n\nWe will not enroll neonates (less than one month old).\n\n* We may enroll adults who are unable to consent (i.e., an individual who is impaired at the time of consent) in this protocol if he\u002Fshe is the only person in his\u002Fher family who has the SF, is symptomatic of the disease, or is in the age range to receive screening for the disease.\n* We may enroll women who are pregnant in this protocol and women who become pregnant during the study can continue their participation. We will not perform prenatal genetic testing.\n* NIH staff members are not prohibited from enrollment if they meet the study s eligibility criteria. The study team will make every effort to protect the confidentiality of the NIH staff member s health information, to minimize any pressure on or discomfort of the NIH staff\n\nmember and provide a copy of the NIH Frequently Asked Questions (FAQs) for Staff Who are Considering Participation in NIH Research , before consent is obtained.","1 Month","105 Years",{"count":307,"type":21},5000,"Background:\n\nGenes are the instructions a person s body uses to function. Genome sequencing reads through all of a person s genes. Everyone has many gene variants, and most do not cause disease. Some gene variants called secondary findings may be important for a person s health even if they are not related to the reason why a person had genome sequencing done. Researchers want to learn more about what it means to have a secondary finding.\n\nObjectives:\n\nTo learn about how gene variants may affect a person s health.\n\nTo learn about how people understand their genetic test results.\n\nEligibility:\n\nPeople with secondary findings from genetic testing done as part of a research study, clinical care, or other methods.\n\nDesign:\n\nParticipants may be asked to do an online survey and phone interview to ask what they think about their results, their healthcare, and if they talk with their family about the result.\n\nEligible participants may be offered a visit to the NIH Clinical Center where they will be evaluated for health problems related to the secondary finding.\n\nDNA samples that were already collected may be studied.\n\nParticipants may be asked to send in a second DNA sample (blood or saliva). These will be used to verify any findings.\n\nParticipants who have a secondary finding can get genetic counseling.",[32,30],[311,312,313,314,315],"Genome Sequencing","Secondary Findings","Return of Results","Natural History","Exome Sequencing","2026-06-17",{"date":318,"type":50},"2026-06-18",{"date":320,"type":50},"2014-09-16",{"date":322,"type":21},"2028-12-31",{"name":324,"class":325},"National Human Genome Research Institute (NHGRI)","NIH",1,{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":338,"conditions":339,"keywords":341,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":326},"100642750","phase-2-ql1706-combined-with-standard-therapy-for-conversion-therapy-of-synchronous-liver-metastases-from-colon-cancer-a-multicenter-single-arm-exploratory-study-100642750","NCT07649473","QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study","Inclusion Criteria:\n\n* Aged 18 to 70 years, male or female.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* Histologically or cytologically confirmed colon adenocarcinoma, with pathologically or radiographically verified liver-only metastases.\n* Microsatellite stable (MSS) \u002F proficient mismatch repair (pMMR) confirmed by immunohistochemistry (IHC) or polymerase chain reaction (PCR).\n* No prior local or systemic anti-tumor therapy for colon cancer liver metastases, including but not limited to targeted therapy, immunotherapy, systemic or hepatic arterial infusion chemotherapy, radiotherapy and surgery.\n* Inclusion criteria for liver metastases: ① More than 5 liver metastatic lesions, with at least one lesion measuring less than 3 cm in diameter; ② Child-Pugh Class A; ③ Future Liver Remnant (FLR) \u002F Standard Liver Volume (SLV) \\> 30% for patients without liver cirrhosis, or \\> 40% for patients with liver cirrhosis; ④ Exclude lesions involving complicated surgical sites, such as biliary tract reconstruction, vascular reconstruction, invasion of hepatic hilum, portal vein or inferior vena cava.\n* At least one radiographically measurable lesion per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).\n* Expected survival of no less than 12 weeks.\n* Laboratory test results meet the following criteria within 7 days prior to the first study drug administration (No blood products, hematopoietic growth factors, albumin or other corrective medications deemed necessary by the investigator shall be administered within 14 days before testing):\n\n  1. Biochemistry: Alkaline phosphatase (ALP), alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 3 × upper limit of normal (ULN), or ≤ 5 × ULN in patients with liver metastases; Total bilirubin (TBIL) ≤ 1.5 × ULN, or ≤ 2 × ULN in patients with liver metastases; Serum creatinine ≤ 1.5 × ULN, or creatinine clearance \\> 50 mL\u002Fmin (calculated via Cockcroft-Gault formula).\n  2. Hematology: Hemoglobin (Hb) ≥ 9.0 g\u002FdL; No red blood cell transfusion within 1 week (including the test day) before baseline Hb test; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet count ≥ 100 × 10⁹\u002FL; No platelet transfusion within 1 week (including the test day) before baseline platelet test.\n  3. Coagulation function: International Normalized Ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. For subjects receiving prophylactic anticoagulation without active bleeding (no bleeding within the past 14 days), INR ≤ 2 × ULN and APTT within normal range.\n  4. Urinalysis: Urinary protein ≤ 30 mg\u002FdL (1+) by dipstick or routine urinalysis. If urine protein ≥ 2+, 24-hour urinary protein quantification shall be less than 1 g\u002F24h.\n* No contraindications to radiotherapy, chemotherapy or immunotherapy.\n* For female subjects of childbearing potential: serum pregnancy test must be negative within 7 days prior to enrollment. They must agree to use effective contraception throughout the study and for 5 months after the last study drug administration. Male subjects with partners of childbearing potential must also use effective contraception during the study and for 5 months after the last dose. Lactating women are excluded.\n* Subjects must be fully informed of the study prior to enrollment, voluntarily sign the written informed consent form, and be willing and able to comply with all scheduled visits, treatment plans, laboratory tests and other study procedures.\n\nExclusion Criteria:\n\n* Confirmed non-adenocarcinoma pathological types via histopathology or cytopathology, including squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc. For mixed pathological types, eligibility is determined by the predominant component; patients are eligible only if a pathologist confirms the adenocarcinoma component accounts for more than 70%. Patients with primary appendiceal tumors are excluded.\n* Presence of distant metastases at sites other than the liver.\n* Prior systemic treatment with anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies or other immunotherapeutic agents, or the CAPOX regimen. Prior radiotherapy for liver metastases, or prior radiation exposure to normal liver tissue adjacent to the planned irradiation field.\n* History of other malignant tumors within 5 years prior to enrollment, except cured carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, radically treated localized prostate cancer, and radically treated ductal carcinoma in situ.\n* Active autoimmune diseases requiring systemic treatment (with immunomodulators, corticosteroids or immunosuppressants) within the past 2 years. Replacement therapies such as thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency are permitted and not regarded as systemic immunosuppressive treatment.\n* Immunodeficiency, or receipt of long-term systemic corticosteroids (prednisone equivalent \\> 10 mg per day) or other immunosuppressants within 7 days before enrollment or anticipated during study treatment.\n* Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites.\n* Tumor-related complications such as bleeding, perforation or intra-abdominal infection within 3 months prior to enrollment.\n* Clinically significant bleeding symptoms or high bleeding risk within 3 months prior to enrollment, including gastrointestinal hemorrhage, gastroesophageal varices, bleeding gastric ulcer, hematochezia, hematemesis or hemoptysis. Presence of gastrointestinal disorders including active peptic ulcer, ulcerative colitis, gastrointestinal perforation, unhealed gastrointestinal fistula, malabsorption syndrome or uncontrolled inflammatory bowel disease.\n* Thrombotic or thromboembolic events including cerebrovascular accident, pulmonary embolism and deep vein thrombosis within 6 months prior to enrollment.\n* Medical history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonia or interstitial lung disease; or evidence of active pneumonia detected on contrast-enhanced chest CT.\n* Any significant clinical or laboratory abnormalities judged by the investigator to compromise safety assessment, including uncontrolled active infection, poorly controlled diabetes, hypertension unresponsive to single-agent therapy, Grade ≥ 2 peripheral neuropathy, congestive heart failure, New York Heart Association (NYHA) Class ≥ II cardiac disease, myocardial infarction within 3 months prior to enrollment, unstable arrhythmia, unstable angina, chronic kidney disease and thyroid dysfunction.\n* Major surgery performed within 28 days prior to enrollment without complete postoperative recovery.\n* Active infection requiring systemic oral or intravenous treatment within 2 weeks prior to enrollment (excluding viral hepatitis and prophylactic medication).\n* Patients with active tuberculosis, or those who received anti-tuberculosis therapy within 1 year prior to enrollment.\n* For patients positive for hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb), HBV-DNA must be less than 500 IU\u002FmL. Patients with active hepatitis B must have received antiviral therapy for at least 14 days before enrollment (e.g., entecavir or tenofovir per local guidelines) and agree to continue effective antiviral treatment throughout the study. For patients positive for HCV antibody, HCV-RNA testing is required; those with HCV-RNA \\> 1000 copies\u002FmL will be excluded.\n* Positive human immunodeficiency virus (HIV) antibody.\n* Administration of any live vaccine (e.g., influenza vaccine, varicella vaccine) within 28 days prior to enrollment.\n* Prior allogeneic bone marrow transplantation or solid organ transplantation.\n* Known allergy to any study drug or its excipients.\n* History of uncorrected serum electrolyte disorders (e.g., hypokalemia, hypocalcemia, hypomagnesemia).\n* Participation in other interventional clinical studies within 28 days prior to enrollment.\n* Presence of clinically significant underlying diseases or other conditions judged by the investigator to interfere with study drug administration or protocol compliance.","70 Years",{"count":335,"type":21},30,[337],"PHASE2","This is a single-arm clinical study aiming to enroll 30 colon cancer patients with liver-only metastases. All eligible participants will undergo screening and enrollment after signing the informed consent form.\n\nAll patients will receive stereotactic body radiation therapy (SBRT) targeting 1 to 3 liver lesions (each \\\u003C 3 cm) at a total dose of 50 Gy delivered in 5 fractions. For lesions adjacent to the liver capsule, portal vein or bile duct, the target volume can be expanded by 5-10 mm outside the visible lesion boundary. One week after radiotherapy completion, patients will be treated with QL1706 (Apalitamab-Tovorizumab, 5 mg\u002Fkg, iv, Q3W) combined with CAPOX plus bevacizumab.\n\nPreoperative treatment consists of up to 6 cycles, with each cycle lasting 3 weeks. Efficacy assessment will be conducted every 2 cycles. The investigator or multidisciplinary team (MDT) will decide to initiate curative treatment (surgical resection or radiofrequency ablation of liver metastases, combined with synchronous or staged resection of primary colon lesion) or continue conversion therapy. Surgery shall be scheduled 6 weeks after the final dose of bevacizumab. During the preoperative waiting period, one extra cycle of QL1706 (5 mg\u002Fkg, iv, Q3W) plus CAPOX is permitted. The interval between the last immunochemotherapy administration and surgery is required to be 2-3 weeks.\n\nAdjuvant therapy is scheduled to start 3 weeks after surgery, and must be initiated no later than 2 months postoperatively. The investigator will determine the use of QL1706 and\u002For bevacizumab in adjuvant setting according to individual patient conditions. If the time from surgery to adjuvant therapy is less than 4 weeks, the first postoperative cycle will use QL1706 (5 mg\u002Fkg, iv, Q3W) combined with CAPOX only. Postoperative QL1706 maintenance treatment will not exceed 1 year. Patients receiving postoperative systemic adjuvant chemotherapy will complete 8 cycles of perioperative CAPOX with or without bevacizumab.\n\nPatients with progressive disease (PD) or those who fail conversion therapy within 18 weeks will switch to alternative systemic regimens in accordance with the 2025 guidelines issued by the Chinese Society of Clinical Oncology (CSCO) and the National Comprehensive Cancer Network (NCCN).\n\nCAPOX + bevacizumab regimen (repeated every 3 weeks):\n\nOxaliplatin: 130 mg\u002Fm², intravenous infusion over 2 hours, d1; Capecitabine: 1000 mg\u002Fm² per dose, po, bid, d1-14; Bevacizumab: 7.5 mg\u002Fkg, ivgtt, d1.",[32,340],"Synchronous Liver Metastases",[342,343,344,345],"QL1706","colon cancer","synchronous liver metastases","conversion","2026-06-14",{"date":348,"type":50},"2026-06-16",{"date":350,"type":21},"2026-08-15",{"date":352,"type":21},"2033-12-31",{"name":354,"class":57},"Fujian Medical University",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":361,"eligibilityCriteria":362,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":22,"phases":364,"briefSummary":365,"conditions":366,"keywords":4,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":4},"100643098","icg-in-colon-cancer-100643098","NCT07638956","ICG in Colon Cancer","A Prospective Study of Indocyanine Green (ICG) Fluorescence-Guided Lymphatic Mapping During Laparoscopic Colon Cancer Resection","ICG","Inclusion Criteria:\n\nAge \\>= 18 years.\n\n\\- Histologically confirmed colon adenocarcinoma.\n\nExclusion Criteria:\n\n* Emergency surgery (obstruction\u002Fperforation with sepsis) requiring urgent operation.\n* Known allergy or contraindication to ICG (including prior anaphylaxis to ICG; severe hypersensitivity history per anesthesia assessment).\n* Pregnancy or breastfeeding.\n* Severe hepatic failure (because ICG clearance is hepatobiliary) or other contraindication determined by anesthesia team.\n* Planned palliative resection only.\n* ASA physical status IV or patients otherwise deemed unfit for elective curative colectomy.",{"count":7,"type":21},[24],"The aim of this study is to evaluate the role of indocyanine green (ICG) injection in fluorescence-guided lymphatic mapping during laparoscopic colon cancer resection. This is a single-center prospective single-arm pilot clinical study that will include at least 25 patients with resectable colon cancer. All enrolled patients will undergo intraoperative subserosal ICG-guided lymphatic mapping before dissection, and intravenous ICG perfusion assessment before anastomosis. The primary goal is to determine the proportion of analyzable pN+ patients in whom all metastatic lymph nodes identified on final histopathology are located within the ICG-mapped lymphatic basin.",[32,367],"ICG (Indocyanine Green)","2026-06-10",{"date":370,"type":50},"2026-06-12",{"date":372,"type":21},"2026-06-01",{"date":374,"type":21},"2028-11-01",{"name":376,"class":57},"Tanta University",{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":383,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":22,"phases":387,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":409},"100593833","phase-2-a-study-of-fruquintinib-plus-folfiri-as-second-line-treatment-for-participants-with-metastatic-colorectal-cancer-fruitful-100593833","NCT07011576","A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","FRUITFUL","Key Inclusion Criteria:\n\n* Confirmed mCRC ; histologically documented adenocarcinoma of the colon or rectum with at least one measurable lesion according to RECIST v1.\n* Genetic aberrations are allowed, except for microsatellite instability high (MSI-H) and BRAF V600\n* Participants must have received first-line therapy for mCRC that included oxaliplatin, a fluoropyrimidine, and a BEV-based agent. FOLFOXIRI, BEV, and SOX\u002FBEV regimes are not permitted. A minimum of 2 cycles of first line of therapy must have been completed.\n* At least 18 years-of-age at the time of signature of the Informed Consent Form (ICF)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2\n\nKey Exclusion Criteria:\n\n* Current treatment with other anticancer treatments within 21 days of the first dose of study treatment\n* Major surgery within 4 weeks of the first planned dose of study treatment\n* More than one prior systemic treatment for mCRC or any prior systemic treatment including FOLFIRI or irinotecan-based therapy.\n* Participants who received oxaliplatin and fluoropyrimidine in the first line neoadjuvant or adjuvant setting (prior to Metastatic diagnosis) and progressed within 6 months are not eligible due to lack of BEV exposure.\n* Uncontrolled, symptomatic brain metastases\n* Uncontrolled, symptomatic gastrointestinal disease\n* Participants with uncontrolled hypertension\n* Women who are pregnant, nursing, or plan to become pregnant while in the study and for at least 6 months after the last administration of study chemotherapy\n* Men who plan to father a child while in the study and for at least 6 months after the last administration of study chemotherapy\n* Documented major electrocardiogram (ECG) abnormalities which are clinically significant.\n* Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment\n* Presence of other active invasive cancers other than the one treated in this study within 5 years prior to screening",{"count":386,"type":21},60,[337],"This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to:\n\n* Evaluate the efficacy of the combination of fruquintinib + FOLFIRI in the 2nd-line mCRC setting\n* Evaluate the safety of the combination of fruquintinib + FOLFIRI",[32,44,390,391],"Colorectal Cancer","Colorectal Cancer (CRC)",[393,32,394,395,396,397,398,399,400,401],"Colorectal cancer","Rectal cancer","Metastatic colorectal cancer","mCRC","VEGFR inhibitor","Fruquintinib","FOLFIRI","Second line","2L mCRC",{"date":370,"type":50},{"date":404,"type":50},"2025-09-29",{"date":406,"type":21},"2027-06",{"name":408,"class":57},"SCRI Development Innovations, LLC",14,{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":436,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":451,"startDateStruct":452,"completionDateStruct":454,"leadSponsor":456,"locationsCount":458},"100520064","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-mesothelin-targeting-logic-gated-car-t-in-participants-with-solid-tumors-that-express-msln-and-have-lost-hla-a02-expression-100520064","NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","A Seamless Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","EVEREST-2","Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of ≥3 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of infusion\n6. Radiotherapy within 28 days of infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion",{"count":419,"type":21},474,[243,337],"The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression.\n\nThe main questions this study aims to answer are:\n\nPhase 1: What is the recommended dose that is safe for patients\n\nPhase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells\n\nParticipants will be required to perform study procedures and assessments, and will also receive the following study treatments:\n\nEnrollment and Apheresis in BASECAMP-1 (NCT04981119)\n\nPreconditioning Lymphodepletion (PCLD) Regimen\n\nTmod CAR T cells at the assigned dose",[423,390,424,425,426,427,428,429,430,431,32,44,251,41,432,132,433,434,39,435],"Solid Tumor, Adult","NSCLC","Non Small Cell Lung Cancer","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreas Cancer","Pancreatic Neoplasm","Colorectal Adenocarcinoma","CRC","Ovarian Neoplasms","Mesothelioma, Malignant","Ovary Cancer","MESOM",[437,438,439,440,441,442,443,444,258,445,446,447,251,448,431,390,39,424,449,435,41,132,450],"CAR T Cell","Solid Tumors","Autologous","T Cell","Mesothelin","MSLN","HLA-A2","Solid Tumors expressing MSLN","Cell Therapy","Gene Therapy","blocker","PANC","OVCA","Logic-gate",{"date":370,"type":50},{"date":453,"type":50},"2024-04-03",{"date":455,"type":21},"2029-06",{"name":457,"class":89},"A2 Biotherapeutics Inc.",12,{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":465,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":469,"conditions":470,"keywords":472,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":297},"100457664","phase-2-single-arm-study-of-neoadjuvant-dostarlimab-in-stage-ii-and-iii-deficient-mismatch-repair-colon-cancers-100457664","NCT05239546","Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers","Phase II, Single Arm Study of Neoadjuvant Dostarlimab (TSR-042) in Stage II and III Deficient Mismatch Repair Colon Cancers","NAIO","Inclusion Criteria:\n\n* Capable of understanding and complying with the protocol requirements and have signed the informed consent document. Patients with mild cognitive impairment may be considered for enrollment in the study if their legally authorized representative provides written informed consent for the patient.\n* 18 years or older in age\n* Biopsy proven dMMR (by IHC), Stage II or III colon cancer per CT imaging correlation with AJCC 8th edition, 2017, amendable to en block surgical resection as determined by colorectal surgeon.\n* Biopsy specimen for diagnosis of dMMR Colon cancer should have enough tissue for minimum 4 and max 6 adjacent unstained FFPE slides (4µm each) as determined by Protocol Pathologist Dr. Anthony Snow for CD3+ and CD8+ analysis. If there is not enough tissue present in original sample, a repeat colonoscopy and biopsy may be performed; otherwise patient is not eligible.\n* Potentially surgically resectable Stage II or III patients who are willing to forgo surgical resection if study endpoints are met. Patient with easily manageable bowel changes amenable to laxatives or stool softeners as outpatient per assessment by colorectal surgery are allowed. (See exclusion criteria #2)\n* ECOG performance status less than or equal to 1\n* Absence of metastatic disease on CT CAP with Contrast within 28 days from treatment start\n* Absolute neutrophil count greater than or equal to 1,500\u002FµL\n* Platelets greater than or equal to 100,000\u002FµL\n* Hemoglobin greater than or equal to 9 g\u002FdL\n* Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) or calculated creatinine clearance 60mL\u002Fmin using the Cockcroft-Gault equation\n* Total bilirubin less than or equal to 1.5 x ULN (less than or equal to 2.0 in patients with known Gilberts syndrome) OR direct bilirubin less than or equal to 1 x ULN\n* Aspartate aminotransferase and alanine aminotransferase less than or equal to 3.0 x ULN\n* International normalized ratio (INR) or prothrombin time (PT) less than or equal to 1.5× ULN unless patient is receiving anticoagulant therapy if PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants. Activated partial thromboplastin time (aPTT) less than or equal to 1.5× ULN unless patient is receiving anticoagulant therapy if PT or PTT is within therapeutic range of intended use of anticoagulants\n* Participants of childbearing potential must have a negative serum pregnancy test within 72 hours prior to taking study treatment and agree to use an adequate method of contraception from screening through 180 days after the last dose of study treatment. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.\n* For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner starting with first dose of study treatment through 180 days after the last dose of study treatment. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient.\n\nExclusion Criteria:\n\n* Synchronous primary tumor (i.e. more than 1)\n* Obstruction or perforation requiring diverting ostomy or immediate resection, or bright red blood per rectum requiring urgent blood transfusion, from their primary tumor.\n* Clinical T4b tumors\n* Known hypersensitivity to dostarlimab components or excipients.\n* Major surgery less than or equal to 3 weeks prior to initiating protocol therapy\n* Received investigational therapy less than or equal to 3 months, or within a time interval less than at least 5 half- lives of the investigational agent, whichever is shorter, prior initiating protocol therapy.\n* Heavy bleeding from the colon cancer tumors requiring PRBC transfusions that would require palliative surgical resection\n* Concurrent, clinically significant, active malignancies within two years of study enrollment.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, glucocorticoids, or immunosuppressive drugs). Other than Replacement hormone therapy with thyroxine for hypothyroidism , insulin for T1 diabetes mellitus , or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.)\n* Diagnosis of immunodeficiency or has received any systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy.\n* History of greater than or equal to Grade 3 immune-related AE with prior immunotherapy, except for non-clinically significant lab abnormalities.\n* Patients with known HIV (Human Immunodeficiency Virus) infection on effective retroviral therapy regardless of CD4 count who have had an opportunistic infection within the past 12 months.\n* Organ transplant recipients on immunosuppressive medications\n* Patients with chronic HBV infection with active disease who meet the criteria for anti HBV therapy but not on suppressive antiviral therapy prior to initiation of treatment of this protocol are excluded. Also, patients with history of HCV infection that have not completed curative antiviral treatment and the HCV viral load is not below the limit of quantification areexcluded.(e.g. a patient who is HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution is eligible.)\n* Prior history of interstitial lung disease.\n* Received a live vaccine within 30 days of initiating protocol therapy.\n* Not enough tissue for confirming dMMR status and CD3+ \u002FCD8+ testing\n* 19\\. Patients with severe cognitive impairment.",{"count":7,"type":21},[337],"This is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.",[32,471],"dMMR Colorectal Cancer",[473,474,475,476,477,478,479],"Colon cancer","dMMR","Deficient mismatch repair colon cancer","MSI-High","MSI-H","Non-operative management","No surgery",{"date":370,"type":50},{"date":482,"type":50},"2023-03-24",{"date":484,"type":21},"2029-06-30",{"name":486,"class":57},"University of Iowa",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":497,"conditions":498,"keywords":502,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":520},"100617629","phase-1-a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mssmsi-l-colorectal-cancer-100617629","NCT07321106","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS\u002FMSI-L Colorectal Cancer","A Phase 1, First-in-human (FIH), Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic Microsatellite Stable (MSS)\u002FMicrosatellite Instability Low (MSI-L) Colorectal Cancer","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Participant with MSS\u002FMSI-L CRC, who has exhausted at least one prior line of standard systemic therapy for their current malignancy.\n* Participant with genomic aberrations, including but not limited to BRAFV600E mutations and HER2 amplifications, for which FDA-approved targeted therapies are available, must:\n\n  * Have received prior treatment with applicable FDA-approved targeted therapies AND\n  * Either have experienced disease progression, be refractory, or be intolerant to directed molecular therapy.\n* Participant able to provide archival tissue sample or fresh biopsy tissue sample\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Participant whose CRC tumor tissues have been identified as dMMR or MSI-H\n* Known history of solid organ or tissue transplant; history of interstitial lung disease or non-infectious pneumonitis.\n* Untreated central nervous system (CNS) metastatic disease.\n* Active autoimmune disease that has required systemic treatment within the past 2 years (participants with hormone replacement therapy for adequately controlled endocrinopathy are allowed in the study).\n* History of recent infection (within 4 weeks of C1D1) considered to be caused by one of the pathogens: HSV1, HSV2, VZV, EBV, CMV, measles, Influenza A, Zika virus, Chikungunya virus, mycoplasma pneumonia, Campylobacter jejuni, or enterovirus D68.\n* Known seropositive for human immunodeficiency virus, hepatitis B surface antigen, or antibody to hepatitis C virus with confirmatory testing and requiring anti-viral therapy.\n* History of Steven's Johnson's syndrome or toxic epidermal necrolysis syndrome.\n* Significant medical comorbidities, including uncontrolled hypertension (diastolic blood pressure \\>115 mm Hg), unstable angina, congestive heart failure (greater than New York Heart Association class II), severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia, poorly controlled diabetes, severe chronic pulmonary disease, coronary angioplasty, or myocardial infarction within 6 months prior to screening, or uncontrolled atrial or ventricular cardiac arrhythmias.\n* Congenital long QT syndrome or a corrected QT interval (QTc) ≥480 ms at screening (unless secondary to pacemaker or bundle branch block).\n* Active second primary malignancy within 3 years of Screening other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ of the breast",{"count":495,"type":21},80,[243],"This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)\u002FMicrosatellite Instability Low (MSI-L) Colorectal Cancer",[390,391,499,431,500,32,501],"Colorectal (Colon or Rectal) Cancer","Metastatic Colon Cancer","Advanced Colorectal Cancer",[503,504,505,506,507,508,509,510,511],"Oncology","Solid Tumor","Phase 1","First-in-Human","Dose Escalation","Open-Label","T-Cell Engager","TCE","CartographyBio","2026-06-09",{"date":368,"type":50},{"date":515,"type":50},"2026-01-15",{"date":517,"type":21},"2029-10",{"name":519,"class":89},"Cartography Biosciences",8,{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":22,"phases":530,"briefSummary":531,"conditions":532,"keywords":535,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":520},"100461030","phase-1-safety-and-tolerability-of-pb-dotam-grpr1-in-adult-subjects-with-recurrent-or-metastatic-grpr-expressing-tumors-100461030","NCT05283330","Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors","A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors","1. Adult participants (age ≥ 18 years old) with any of the following advanced or metastatic solid tumors (documented history of histologically confirmed diagnosis):\n\n   1. Metastatic castration-resistant prostate cancer (mCRPC) including neuroendocrine prostate cancer (NEPC) (enrolled only in SAD and MAD Q6W)\n   2. HR+\u002FHER2- breast cancer (estrogen receptor\u002FER expression \\>10% of tumor cell nuclei stain, regardless of progesterone receptor\u002FPgR expression); HER2-negative including HER2-low (as per relevant ASCO\u002FCAP guidelines)\n   3. Colorectal cancer\n   4. Cervical cancer\n   5. Non-small-cell lung cancer (NSCLC)\n   6. Recurrent glioblastoma (only enrolled in MAD Q4W cohorts) with evidence of recurrent disease (RD) demonstrated by disease progression using modified Response Assessment in Neuro-Oncology (RANO 2.0) criteria. Note: If surgery is performed for GBM recurrence, pre-surgery MRI will be used for confirmation of RD and residual and measurable disease post-surgery is not required but surgery must have confirmed the recurrence diagnosis by MRI.\n2. Capable of giving signed informed consent\n3. All participants must have progressed on at least 2 prior systemic therapies, except for recurrent GB\n4. For participants with mCRPC: Prior orchiectomy and\u002For ongoing androgen deprivation therapy and a castrate level of serum testosterone (\\\u003C50 ng\u002FdL or \\\u003C1.7 nmol\u002FL)\n5. Presence of at least 1 measurable lesion per RECIST 1.1 as assessed by the Investigator (not applicable for GBM). At least 1 identified measurable lesion must show GRPR uptake in 203Pb-DOTAM-GRPR1 SPECT\u002FCT (uptake greater than that of the background) as assessed by the Investigator.\n6. For participants with prostate cancer that do not have measurable soft tissue disease, 203Pb-DOTAM-GRPR1 uptake in bone lesions \\> uptake in background is acceptable for eligibility.\n7. Eastern Cooperative Oncology Group (ECOG) status 0-1. Participants with ECOG status of 2 may be approved on a case-by-case basis in discussion with the Sponsor.\n8. Adequate bone marrow, hepatic, and renal function, as assessed by the following laboratory requirements:\n\n   1. White blood cell (WBC) ≥3000\u002F mm3 (≥ 3 x 109\u002FL)\n   2. Absolute neutrophil count (ANC) ≥1500\u002Fmm3 (≥1.5 x 109\u002FL)\n   3. Platelets ≥100,000\u002Fmm3 (≥ 100 x 109\u002FL)\n   4. Hemoglobin (Hb) ≥9.0 g\u002FdL\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3x upper limit of normal (ULN) or ≤ 5 x ULN in the presence of liver metastases\n   6. Total bilirubin: ≤1.5 x ULN, except if documented history of Gilbert's disease who are eligible if total bilirubin ≤ 3 x ULN\n   7. Adequate renal function defined by creatinine clearance (CLCR) ≥ 60 mL\u002Fmin calculated as follows: CLCR = eGFR in ml\u002Fmin\u002F1.73 m2 calculated by the Modified Diet in Renal Disease (MDRD) x participant body surface area (BSA) in m2 ÷ 1.73\n   8. Serum amylase and\u002For lipase ≤1.5 x ULN\n9. For women of childbearing potential (WOCBP) and men with partners of childbearing potential: be willing to use highly effective methods of contraception or sexual abstinence, if part of participant's lifestyle, throughout the study and for 7 months for WOCBP, 4 months for men after the last \\[212Pb\\]Pb-DOTAM-GRPR1 administration or for 10 days following \\[203Pb\\]Pb-DOTAM-GRPR1 administration and participant is not proceeding to 212Pb-DOTAM-GRPR1 treatment, as outlined in protocol.\n\n   Participants with Recurrent Glioblastoma:\n10. Having first or second glioblastoma recurrence, after standard therapy that includes prior radiation therapy (RT) and at least 12 weeks from completion of RT prior to first administration of 212Pb-DOTAM-GRPR1. In case surgery has been performed for GBM recurrence, the surgery has to be completed at least 4 weeks prior to 212Pb-DOTAM-GRPR1 treatment start, with post-surgery recovery without any complications related to surgical procedure.\n11. Presence of 203Pb-DOTAM-GRPR1 uptake by SPECT\u002FCT scan in the tumor lesion(s).\n12. Presence of Gadolinium enhancement in the MRI in the tumor lesion(s) shown at the time of diagnosis of tumor recurrence.",{"count":529,"type":21},48,[243],"A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors",[31,30,32,424,533,248,534],"mCRPC (Metastatic Castration-resistant Prostate Cancer)","Nonsmall Cell Lung Cancer",[536,537,538,539,540,541,542,390,31,543,544,545,546,547,548,549,550],"Metastatic Cancer","Advanced Cancer","Recurrent Cancer","Prostate Cancer, Castration-Resistant","Metastatic Prostate Cancer","Breast Cancer, Hormone Receptor Positive","Non-Small Cell Lung Cancer","Glioblastoma, Recurrent","Radioligand Therapy","Targeted Radiation Therapy","Gastrin-Releasing Peptide Receptor or Bombesin receptor subtype-2","Targeted Alpha Therapy","Lead-212 Radiopharmaceutical Therapy","Lead-203 Radiopharmaceutical Diagnostic","SPECT\u002FCT",{"date":552,"type":50},"2026-06-11",{"date":554,"type":50},"2022-12-22",{"date":556,"type":21},"2032-05",{"name":558,"class":89},"Orano Med Theranostics, SAS",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":569,"conditions":570,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":581},"100603165","leakage-rate-of-ileo-colic-sutured-anastomosis-after-right-hemicolectomy-100603165","NCT07132970","Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy","Assessment of the Leakage Rate of Ileo-colic Sutured Anastomoses Using a Polydioxanone Based Suture Material After Laparoscopic or Open Right Hemicolectomy to Treat Malignancy","LICOSARH","Inclusion Criteria:\n\n* Patients undergoing a primary, elective either open or laparoscopic right hemicolectomy or right extended hemicolectomy due to malignancy with the creation of an intracorporeal or extracorporeal ileo-colic anastomosis.\n* Either complete hand-sewn anastomosis or partial sutured anastomosis (e.g. combination of stapling and suturing)\n* Open or laparoscopic as well as conversion from open to laparoscopic surgery\n* Absence of peritoneal carcinomatosis\n* Absence of vascular, nervous or bone infiltration\n* Age ≥ 18 years\n* Written data protection declaration (Written Informed consent)\n\nExclusion Criteria:\n\n* Left hemicolectomy or left extended hemicolectomy or sigma resection\n* Inflammatory bowel disease (e.g. Crohn´s disease)\n* Emergency surgery\n* Previous abdominal surgery with bowel resection\n* Re-operation of an anastomosis (anastomosis revision surgery)\n* Need for stoma creation\n* Non-compliant patients\n* Participation in an interventional randomized controlled study (RCT)",{"count":568,"type":21},249,"The primary aim of the study is to show that the ileo-colic anastomosis leakage rate until the first 30 days after surgery using MonoPlus® suture material for anastomosis construction after right hemicolectomy is not inferior to the anastomosis leakage rate published in the literature for totally handsewn or stapled-handsewn ileo-colic anastomosis.",[571,32,572],"Anastomotic Leak","Right Hemicolectomy","2026-06-08",{"date":512,"type":50},{"date":576,"type":50},"2026-01-26",{"date":578,"type":21},"2028-03",{"name":580,"class":89},"Aesculap AG",4,{"id":583,"slug":584,"hasResults":12,"nctId":585,"briefTitle":586,"officialTitle":586,"acronym":587,"eligibilityCriteria":588,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":589,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":591,"conditions":592,"keywords":593,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":599,"leadSponsor":601,"locationsCount":326},"100616498","distribution-and-analysis-of-metastatic-lymph-nodes-in-colorectal-cancer-patients-diamond-100616498","NCT07306390","Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)","DIAMOND","Inclusion Criteria:\n\n* Aged between 18 and 80 years\n* Pathologically confirmed adenocarcinoma of the colon or rectum\n* Underwent radical resection for colorectal cancer with a D3 lymphadenectomy and lymph nodes were submitted for pathological examination according to standardized station-based and distance-based protocol\n* No distant metastasis or distant metastasis within 6 months after surgery\n* No history of other malignant tumors or severe systemic diseases\n* No immune diseases or inflammatory bowel diseases\n* Non-emergency surgery\n* With complete clinicopathological and follow-up data\n\nExclusion Criteria:\n\n* Pathologically confirmed benign tumors or non-adenocarcinoma malignancies\n* Underwent local excision or palliative resection\n* Regional lymph nodes were not dissected or submitted for pathological examination according to the unified station-based or distance-based protocol\n* With distant metastasis or distant metastasis within 6 months after surgery\n* Dual or multiple primary colorectal cancers or concurrent other malignant tumors\n* Had a previous diagnosis of immune diseases or inflammatory bowel disease such as ulcerative colitis or Crohn's disease\n* Underwent emergency surgery\n* Had incomplete clinicopathological or follow-up data",{"count":590,"type":21},1200,"The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients. The main question it aims to answer is:\n\n* What is the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer?\n* Can the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer guide clinical practice? Participants should undergo regular follow-up examinations for at least 5 years after the surgery.",[32,44],[390,594,595],"Lymph Node Metastasis","Spatial Distribution","2026-06-07",{"date":512,"type":50},{"date":47,"type":21},{"date":600,"type":21},"2028-01-31",{"name":602,"class":57},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":66,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":610,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":612,"conditions":613,"keywords":614,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":617,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":4,"leadSponsor":622,"locationsCount":326},"100091519","follow-up-study-of-subjects-previously-enrolled-in-poxviral-vector-gene-transfer-studies-100091519","NCT00451022","Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies","Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents","* INCLUSION CRITERIA:\n* Subjects who received poxviral vectors (vaccinia and\u002For fowlpox) or other vaccines utilizing gene transfer or any other immunotherapeutic agent through GMB, UOB and LTIB affiliated trials at the National Cancer Institute, as well as subjects at extramural sites receiving these agents as part of a multi-site trial. Available stored specimens obtained from NCI participants in GMB, UOB, and LTIB affiliated protocols may be transferred to this protocol for storage and eventual future research use.\n* Subjects must be \\>= 18 years of age.\n\nEXCLUSION CRITERIA:\n\nParticipants unwilling to participate.\n\n(Please note, participants may participate in this protocol and, at the same time, participate in an active treatment or continuing care study.)",{"count":611,"type":21},750,"This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene therapy. The genes expressed by poxviral vectors do not become part of the genetic material left behind. Because gene therapy is a somewhat new technology, a prolonged monitoring of patients' health status is necessary, according to new specific reporting requirements for harmful events in patients who undergo such gene therapy studies. The risk of any long-term negative effects from the gene therapy that patients had received is quite small. Still, it is important that there be updates at least annually. This annual monitoring of health status will extend for 15 years, according to guidelines from the Food and Drug Administration, or for as long as patients are willing to participate.\n\nPatients who received poxviral vectors (vaccinia or fowlpox, or both) at the National Cancer Institute, through a trial affiliated with the Laboratory of Tumor Immunology and Biology, may be eligible for this study.\n\nParticipants will be involved in the following forms of data collection:\n\n* Annual medical history and physical examinations for the first 5 years following the last vaccine.\n* Annual telephone contact during the last 10 years.\n* Health status check, including primary cancer status, secondary malignancies, neurologic disorders, autoimmune disorders, and hematologic disorders.\n* Blood tests for the presence of HIV antibodies.\n* Reporting of medical problems, including information on unexpected hospitalizations and medications.\n\nIf a participant has died, the study will document the cause of death and autopsy information if available.",[43,38,30,32,39],[446,615,616,314],"Long Term Survivor","Research Specimen","2026-06-04",{"date":619,"type":50},"2026-06-05",{"date":621,"type":50},"2004-09-13",{"name":623,"class":325},"National Cancer Institute (NCI)",{"id":625,"slug":626,"hasResults":12,"nctId":627,"briefTitle":628,"officialTitle":629,"acronym":4,"eligibilityCriteria":630,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":631,"targetDuration":4,"studyType":22,"phases":633,"briefSummary":634,"conditions":635,"keywords":638,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":649},"100602773","phase-1-a-study-of-phn-012-in-patients-with-advanced-solid-tumors-100602773","NCT07127874","A Study of PHN-012 in Patients With Advanced Solid Tumors","First-in-Human, Phase 1 Study of PHN-012, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Has histologically confirmed, advanced\u002Fmetastatic:\n\n  1. Colorectal adenocarcinoma (CRC), or\n  2. Non-small cell lung cancer (NSCLC), or\n  3. Pancreatic ductal adenocarcinoma (PDAC).\n* Has received at least one prior systemic therapy and radiologically or clinically determined progressive disease during or after the most recent line of therapy, and for whom no further standard therapy is available or who is intolerant to standard therapy.\n* Has measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Has adequate organ function.\n* Has available tumor tissue sample at screening (either an archival specimen or fresh biopsy material).\n\nExclusion Criteria:\n\n* Had prior treatment with any ADC containing topoisomerase-1 inhibiting payload.\n* Has unstable central nervous system metastasis.\n* Has persistent toxicities from previous systemic anti-cancer treatments of Grade \\>1.\n* Has received systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the study drug.\n* Has received wide-field radiotherapy (\\> 30% of marrow-bearing bones) within 28 days, or focal radiation for analgesic purpose or for lytic lesions at risk of fracture within 14 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Had major surgery (not including placement of vascular access device or tumor biopsies) within 28 days prior to first dose of the study drug, or no recovery from side effects of such intervention.\n* Has a history of non-infectious pneumonitis (NIP) \u002F interstitial lung disease (ILD) requiring systemic steroids within 6 months prior to first dose of the study drug, active NIP \u002F ILD or suspected NIP \u002F ILD which cannot be ruled out by imaging for Screening.",{"count":632,"type":21},165,[243],"This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.",[32,42,636,537,637],"Lung Cancer (NSCLC)","Advanced Solid Tumors",[639,640,251,504],"Antibody Drug Conjugate","Carcinoma","2026-06-03",{"date":619,"type":50},{"date":644,"type":50},"2025-09-23",{"date":646,"type":21},"2028-05",{"name":648,"class":89},"Pheon Therapeutics",20,{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":4,"eligibilityCriteria":656,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":657,"targetDuration":4,"studyType":22,"phases":659,"briefSummary":660,"conditions":661,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":326},"100600491","contribution-of-preserving-the-superior-left-colic-artery-to-the-vascularization-of-the-descending-colon-prior-to-colorectal-anastomosis-during-left-sided-or-rectal-resections-for-colorectal-or-ovarian-cancer-revascularisation-colique-100600491","NCT07098182","Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)","Clinical Study Evaluating the Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)","Inclusion Criteria:\n\n* Male\u002F female aged over 18 years,\n* Histologically proven left colon or rectal adenocarcinoma OR ovarian carcinoma (with potential colorectal resection),\n* Scheduled surgery for left colic or rectal carcinoma\u002F\u002F Scheduled surgery for ovarian carcinoma with potential colorectal resection,\n* Surgical indication of colo-rectal resection validated in RCP and confirmed during the operative exploration (ovarian cancer,\n* WHO Status \\\u003C 3\n* Patient who has given informed, written and express consent,\n* Patient (s) affiliated to a French social security.\n\nExclusion Criteria:\n\n* Contraindication to indocyanine green: thyroid adenoma, hyperthyroidism, hypersensitivity or allergy to one of the components, severe renal failure (GFR \\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Patient with a history of abdominal vascular surgery\n* Patient (e) not having left colic artery on vascular mapping of preoperative abdominal-pelvic scanners,\n* Patient whose regular follow-up is not possible for psychological, family, social or geographical reasons,\n* Patient (s) under guardianship, curatorship or safeguard of justice,\n* Pregnant and\u002For breastfeeding patient,",{"count":658,"type":21},50,[24],"Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France.\n\nSurgical resection is a crucial step in the therapeutic management of colorectal cancers. For advanced ovarian cancers, the objective of cytoreductive surgery is to obtain complete macroscopic resection with no visible residual disease. One or more digestive resections are often required to achieve this goal of complete surgery (usually a modified posterior pelvic exenteration with colorectal resection).\n\nA ligation of the inferior mesenteric artery at its origin is classically performed in left colectomies and rectal resection for colorectal cancers. This allows the resection of the colorectal segment with a complete mesocolic lymphadenectomy until the origin of the inferior mesenteric artery and a good mobilization of the descending colon to allow its anastomosis to the underlying rectal stump. This ligation of the inferior mesenteric artery at its origin is also frequently performed in cases of modified posterior pelvic exenteration for ovarian cancer.\n\nRecently, several studies suggest that arterial ligation of the inferior mesenteric artery could be performed below the emergence of the left colic artery. Its preservation requiring a meticulous vascular dissection would allow a better vascularization of the descending colon and of the colorectal anastomosis without affecting the carcinologic quality of the resection and the number of resected lymph-nodes. Indeed, the most feared complication during colorectal anastomosis is the anastomotic leakage whose rates are on average 15% in rectal cancer with low anastomosis and 6% in ovarian cancers.\n\nVerifying the adequate vascularization of the descending colon before performing the colorectal anastomosis is a crucial step in reducing the risk of postoperative fistula. However, quantifying this vascularization is challenging, and several techniques can be used to assess it. The gold standard technique involves measuring arterial pressure using a catheter inserted into the marginal artery of the descending colon. Other non-invasive techniques also use Doppler studies to calculate pressure in the marginal artery or assess oxygen saturation using a sterile sensor.\n\nStudies have shown that the use of indocyanine green in colorectal surgery, particularly to evaluate perfusion before the creation of an anastomosis, significantly reduces the rate of anastomotic leakage. Indocyanine green is a fluorescent dye that, after intravenous injection, binds to plasma proteins and allows tissue perfusion to be visualized using a fluorescence system.\n\nThe objective of this project is to show that the preservation of the left colic artery is possible and allows a better vascularization of the descending colon before colorectal anastomosis.",[44,32,41],"2026-06-02",{"date":617,"type":50},{"date":665,"type":50},"2025-11-27",{"date":667,"type":21},"2026-10",{"name":669,"class":57},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":4,"eligibilityCriteria":676,"healthyVolunteers":66,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":677,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":679,"conditions":680,"keywords":681,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":686,"lastUpdatePostDateStruct":687,"startDateStruct":688,"completionDateStruct":4,"leadSponsor":690,"locationsCount":326},"100060621","collection-of-blood-from-patients-with-cancer-100060621","NCT00034216","Collection of Blood From Patients With Cancer","Biospecimen Acquisition From Human Subjects","* INCLUSION CRITERIA:\n\nPatients with a known or suspected malignancy and healthy volunteers 18 years of age and older are eligible.\n\nPerformance status of ECOG 0, 1, 2, or 3 for admission to this protocol.\n\nAbility to understand and the willingness to sign a written informed consent document.\n\nINCLUSION FOR APHERESIS:\n\nNote: Effective with Amendment CC, participants will no longer be asked to undergo apheresis. This content is being retained for historical reference.\n\nHemoglobin greater than or equal to 10 mg\u002FdL and platelet count \\> 75,000\u002Fmm(3)\n\nWeight greater than 25 kg\n\nHIV negative\n\nProthrombin Time - within normal limits\n\nPartial Thromboplastin Time - within normal limits\n\nMedically indicated central line in place or adequate peripheral venous access\n\nEXCLUSION CRITERIA:\n\nNone.",{"count":678,"type":21},1750,"This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment.\n\nParticipants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment.",[43,30,32,39,38],[682,683,684,314,251,250,685],"Suppressor Cells","T-cells","CD4+ \u002F CD25+ cells","Blood Sample","2026-05-29",{"date":372,"type":50},{"date":689,"type":50},"2002-07-16",{"name":623,"class":325},{"id":692,"slug":693,"hasResults":12,"nctId":694,"briefTitle":695,"officialTitle":696,"acronym":4,"eligibilityCriteria":697,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":698,"enrollmentInfo":699,"targetDuration":4,"studyType":22,"phases":701,"briefSummary":702,"conditions":703,"keywords":705,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":710,"lastUpdatePostDateStruct":711,"startDateStruct":712,"completionDateStruct":714,"leadSponsor":716,"locationsCount":326},"100300428","phase-1-administering-peripheral-blood-lymphocytes-transduced-with-a-murine-t-cell-receptor-recognizing-the-g12v-variant-of-mutated-ras-in-hla-a1101-patients-100300428","NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","A Phase I\u002FII Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","* INCLUSION CRITERIA:\n* Measurable (per RECIST V1.1 criteria, metastatic, or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing, or any other CLIA-certified laboratory test on resected tissue. Patients shown to have tumors expressing G12V mutated NRAS and HRAS will also be eligible as these oncogenes share complete amino acid homology with G12V mutated KRAS for their first 80 N-terminal amino acids, completely encompassing the target epitope.\n* Patients must be HLA-A\\*11:01 positive as confirmed by the NIH Department of Transfusion Medicine.\n* Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.\n* Patients must have:\n\n  * previously received standard systemic therapy for their advanced cancer and have been either non-responders or have recurred, specifically:\n\n    * Patients with metastatic colorectal cancer must have had at least two systemic chemotherapy regimens that include 5FU, leucovorin, bevacizumab, oxaliplatin, and irinotecan (or similar agents), or have contraindications to receiving those medications.\n    * Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications.\n    * Patients with non-small cell lung cancer (NSCLC) must have had appropriate targeted therapy as indicated by abnormalities in ALK, EGFR, or expression of PDL- 1. Other patients must have had platinum-based chemotherapy.\n    * Patients with ovarian cancer or prostate cancer must have had approved first-line chemotherapy.\n\nOR\n\n* declined standard treatment\n* Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients\n\nwith surgically resected brain metastases are eligible.\n\n* Age greater than or equal to 18 years and less than or equal to 72 years.\n* Clinical performance status of ECOG 0 or 1\n* Patients must be willing to practice birth control from the time of enrollment on this study and 12 months after the last dose of combined chemotherapy for women and for 4 months after treatment for men.\n* Women of child-bearing potential must be willing to undergo pregnancy testing prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\nNOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and\u002F or ultrasound may be performed for clarification.\n\n* Serology\n\n  * Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n  * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n* Hematology\n\n  * ANC greater than 1000\u002Fmm\\^3 without the support of filgrastim\n  * WBC greater than or equal to 2500\u002Fmm\\^3\n  * Platelet count greater than or equal to 80,000\u002Fmm\\^3\n  * Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n* Chemistry\n\n  * Serum ALT\u002FAST less than or equal to 5.0 times ULN\n  * Total bilirubin less than or equal to 2.0 mg\u002FdL, except in patients with Gilbert s Syndrome, who must have a total bilirubin less than 3.0 mg\u002FdL.\n* Patients must have either an eGFR \\> 60 mL\u002Fm (based on serum creatinine and lab nomogram) or a formal 6-24h CrCl \\> 60 mL\u002Fm.\n* Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to less than or equal to grade 1.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Subjects must be co-enrolled on protocol 03C0277.\n\nEXCLUSION CRITERIA:\n\n* Large volume pulmonary irradiation.\n* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Concurrent systemic steroid therapy.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n* History of coronary revascularization or ischemic symptoms\n* For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n* For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50% or DLCO less than 60%.\n* Patients who are receiving any other investigational agents.","72 Years",{"count":700,"type":21},110,[243,337],"Background:\n\nA new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells.\n\nObjective:\n\nTo see if anti-KRAS G12 V mTCR cells are safe and can shrink tumors.\n\nEligibility:\n\nAdults at least 18 years old with cancer that has the KRAS G12V molecule on the surface of tumors.\n\nDesign:\n\nIn another protocol, participants will:\n\nBe screened\n\nHave cells harvested and grown\n\nHave leukapheresis\n\nIn this protocol, participants will have the procedures below.\n\nParticipants will be admitted to the hospital.\n\nOver 5 days, participants will get 2 chemotherapy medicines as an infusion via catheter in the upper chest.\n\nA few days later, participants will get the anti-KRAS G12V mTCR cells via catheter.\n\nFor up to 3 days, participants will get a drug to make the cells active.\n\nA day after getting the cells, participants will get a drug to increase their white blood cell count. This will be a shot or injection under the skin.\n\nParticipants will recover in the hospital for 1-2 weeks. They will have lab and blood tests.\n\nParticipants will take an antibiotic for at least 6 months.\n\nParticipants will have visits every few months for 2 years, and then as determined by their doctor.\n\nVisits will be 1-2 days. They will include lab tests, imaging studies, and physical exam. Some visits may include leukapheresis or blood drawn.\n\nParticipants will have blood collected over several years.",[42,36,704,32,44],"Gastrointestinal Cancer",[706,707,708,445,709],"KRAS","HRAS","NRAS","Immunotherapy","2026-05-28",{"date":686,"type":50},{"date":713,"type":50},"2017-09-21",{"date":715,"type":21},"2028-06-29",{"name":623,"class":325},{"id":718,"slug":719,"hasResults":12,"nctId":720,"briefTitle":721,"officialTitle":721,"acronym":4,"eligibilityCriteria":722,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":723,"targetDuration":4,"studyType":22,"phases":725,"briefSummary":726,"conditions":727,"keywords":730,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":733,"lastUpdatePostDateStruct":734,"startDateStruct":736,"completionDateStruct":738,"leadSponsor":740,"locationsCount":326},"100536304","equity-gi-a-prospective-study-to-enhance-quality-inclusivity-and-trial-participation-in-black-patients-with-gastrointestinal-cancer-100536304","NCT06263088","EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.","Inclusion Criteria:\n\n1. Adult ≥ 18 years old.\n2. Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor.\n3. Patient able and willing to comply with study procedures\n4. The patient is able to understand and willing to sign and date the written informed consent form at the screening visit.\n\nExclusion Criteria:\n\n* NONE",{"count":724,"type":21},200,[24],"This research study is being conducted to improve the quality of care of participants who have a diagnosis of gastrointestinal cancer (anal, colon, rectal, esophageal, stomach, small bowel, appendix, pancreas, gall bladder, liver, neuroendocrine tumor of gastrointestinal origin).\n\nThis study has 3 components as follows-\n\n1. Ensuring appropriate biomarker testing and evidence-based care: Biomarkers are molecules in the tumor or blood that indicate normal or abnormal processes in participant's body and may indicate an underlying condition or disease. Various molecules, such as DNA (genes), proteins, or hormones, can serve as biomarkers since they all indicate something about participant's health. Biomarker testing can also help choose participant's treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to participant's treating physician. Participants will receive standard-of-care treatment if participant enroll in this study. Participant will not receive any experimental treatment.\n2. Assistance with clinical trial enrollment. The study team will help participants enroll in a clinical trial appropriate for participant's condition. However, enrolling in a clinical trial is totally up to the participant.\n3. Health literacy: The study team will provide information relevant to participant's diagnosis to enrich participant's understanding of participant's condition and treatment. Investigator will provide questionnaires to assess participant's understanding before and after participant's have been provided with educational\u002Finformational material appropriate for participant's diagnosis.",[704,32,44,28,34,728,729,428,38,138],"Stomach Cancer","Appendix Cancer",[731,732],"Gastrointestinal cancer","African Americans","2026-05-19",{"date":735,"type":50},"2026-05-22",{"date":737,"type":50},"2024-12-01",{"date":739,"type":21},"2026-09-30",{"name":741,"class":57},"Case Comprehensive Cancer Center",{"id":743,"slug":744,"hasResults":12,"nctId":745,"briefTitle":746,"officialTitle":746,"acronym":747,"eligibilityCriteria":748,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":749,"targetDuration":4,"studyType":22,"phases":751,"briefSummary":752,"conditions":753,"keywords":4,"overallStatus":174,"whyStopped":4,"lastUpdateSubmitDate":756,"lastUpdatePostDateStruct":757,"startDateStruct":758,"completionDateStruct":759,"leadSponsor":761,"locationsCount":4},"100638325","statewide-unified-network-for-remote-intervention-of-strength-and-exercise-100638325","NCT07596732","Statewide Unified Network for Remote Intervention of Strength and Exercise","SUNRISE","Inclusion Criteria:\n\n* Gastrointestinal cancer (esophageal, gastric, pancreatic, colon, and rectal) treated with chemotherapy (and other treatments, as clinically indicated) before surgery OR Lung cancer (non-small cell and small-cell) treated with chemotherapy (and other treatments, as clinically indicated) for advanced- or extensive-stage disease.\n* Completion of the modified version of the Physical Activity Readiness Questionnaire.\n\nExclusion Criteria:\n\n* Actively treated for another non-gastrointestinal or non-lung malignancy (surveillance with observation is allowed).\n* Engage in more than 150 minutes per week of aerobic physical activity and two or more sessions of muscle strengthening activity per week over the last three months (self-report).\n* Unable to walk for 6 minutes or two city blocks independently (self-report).\n* Enrollment in another study that intervenes upon physical activity, diet, or body composition as a primary objective (self-report).\n* Unable to read and speak English.\n* No access to a reliable internet connection.\n* Currently an AdventHealth employee.",{"count":750,"type":21},120,[24],"This study will evaluate whether a remotely delivered exercise program can improve chemotherapy tolerability in patients with gastrointestinal or lung cancer receiving chemotherapy.\n\nIn this decentralized, digital randomized clinical trial, up to 120 adults with gastrointestinal or lung cancer will be randomized to either a home-based aerobic and resistance exercise program or home-based progressive stretching program. All study activities will be conducted remotely using digital technologies and home-based assessments. Participants in both groups will receive Bluetooth-enabled wearable devices for monitoring physical activity, body weight, blood pressure, and other health measures.\n\nThe primary objective is to determine whether exercise improves chemotherapy relative dose intensity compared with stretching. The intervention will continue throughout chemotherapy treatment or for up to 32 weeks.",[754,755,428,32,44,39],"Gastric Cancer (Diagnosis)","Esophagus Cancer","2026-05-13",{"date":733,"type":50},{"date":47,"type":21},{"date":760,"type":21},"2027-12-31",{"name":762,"class":57},"AdventHealth Translational Research Institute"]